Project

Targeted immunotherapy for the treatment of T-cell acute lymphoblastic leukemia

Code
365L05618
Duration
01 September 2018 → 31 August 2019
Funding
Funding by bilateral agreement (private and foundations)
Research disciplines
  • Medical and health sciences
    • Cancer therapy
Keywords
leukemia
 
Project description

In this project, we will evaluate a novel therapeutic strategy for the treatment of T-ALL, an aggressive subtype of leukemia. Using novel immunocytokines, we aim to combine direct targeting of the leukemia cells with indirect stimulation of the immune system. In that way, we believe that we can reduce adverse side effects that are associated with current chemotherapy regimens, and build an immunological memory that will prevent putative disease relapse.